Extensor digitorum brevis test and resistance to botulinum toxin type A

Muscle and Nerve

Volumn 26, Issue 6, 2002, Pages 828-831

  Gordon, Paul H ^a   Gooch, Clifton L ^b   Greene, Paul E ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Botulinum toxin; EDB test; Immunoresistance; Nerve conduction studies

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DYSTONIA; HAND MUSCLE; HUMAN; MUSCLE ACTION POTENTIAL; NERVE STIMULATION; PERONEUS NERVE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

ACTION POTENTIALS; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; DRUG RESISTANCE; DYSTONIC DISORDERS; ELECTROPHYSIOLOGY; HUMANS; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE, SKELETAL; PREDICTIVE VALUE OF TESTS;

EID: 0036894887     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.10231     Document Type: Article

References (19)

1. Dressler D, Bigalke H, Rothwell JC. The sternocleidomastoid test: An in vivo assay to investigate botulinum toxin antibody formation in humans. J Nenrol 2000;257:630-632.
2. Goschel H, Wohfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies - Therapeutic consequences. Exp Neurol 1997;147: 96-102.
3. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-483.
4. Greene PE, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with tordcollis. Mov. Disord 1994;9:213-217.
5. Hambleton P, Chohen HE, Palmer BJ, Melling J. Antitoxins and botulinum treatment. BMJ 1992;304:959-960.
6. Hamjian JA, Walker FO, Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve 1994;17:1385-1392.
7. Hatheway CL, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallet M, editors. Therapy With Botulinum Toxin. New York: Marcel Dekker; 1994. p 93-107.
8. Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 1998;64:577-580.
9. Jankovic J, Brin M. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-1194.
10. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
11. Kessler KR, Benecke R. The EDB test - A clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 1997;12:95-99.
12. Schantz EJ, Jautter DA. Standardized assay for Clostridium botulinum toxins. J Assoc Off Anal Chem 1978;61:96-99.
13. Schantz EJ, Johnson EA. Dose standardization of botulinum toxin. Lancet 1990;335:421.
14. Siegel LS. Human response to pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol 1988;26:2351-2356.
15. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology 1997;48: 249-253.
16. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: Type B compared with type A. Neurology 1997;49:189-194.
17. Sloop RR, Cole D, Patel MC. Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals. Mov Disord 2001;16:100-115.
18. Sloop RR, Escutin RO, Matus JA, Cole BA, Peterson GW. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurolo 1996;46:1382-1386.
19. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinnm antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance. Neurology 1993;43:1715-1718.